GlassScriptPhysician profile
Stephen Paul Brackbill
NPI 1437190428
$2,009.40
in general payments reported to CMS, 2019-2025
20 companies · $516 in 2025
The $516 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $58.19 · 2021: $83.08 · 2022: $330 · 2023: $522 · 2024: $221 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.67 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Qol Medical, LLC | $211.13 | 2019-2025 | Sucraid |
| Pfizer INC. | $151.23 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.69 | 2019-2023 | Xifaxan, Plenvu |
| Genzyme Corporation | $101.91 | 2022-2025 | |
| Madrigal Pharmaceuticals | $77.51 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $72.83 | 2019-2024 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $71.35 | 2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $69.81 | 2021-2022 | |
| Janssen Biotech, INC. | $43.64 | 2019-2024 | Stelara |
| Celgene Corporation | $37.73 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $32.25 | 2023 | Rebyota |
| Medtronic, INC. | $31.06 | 2025 | Gi Genius |
| Boston Scientific Corporation | $27.08 | 2025 | Apollo Esg Nxt System |
| Phathom Pharmaceuticals, INC. | $26.55 | 2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $18.93 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $16.36 | 2022 | |
| Merck Sharp & Dohme LLC | $13.99 | 2021 | |
| Amgen INC. | $12.71 | 2023 | Amjevita, Avsola |
| Ucb, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Brackbill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.